In this interview, Abbas Kanani, MRPharmS, Superintendent Pharmacist at Chemist Click, tells us about amyloidosis, a group of rare diseases in which abnormal proteins deposit as amyloid in tissues and organs.
David Nutt FMedSci, Chair Drug Science and PAREA, Prof of Neuropsychopharmacology at Imperial College London, explains why Europe needs to catch up with psychedelic research.
Researchers discover drug combination that could offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.
Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
Reflecting on the recent World Antimicrobial Awareness Week (WAAW 2022), it’s evident that we must continue to raise better awareness and understanding of antimicrobial resistance, which is one of the top 10 global public health threats facing humanity.
After decades of failure for Alzheimer’s researchers, Lecanemab could open the door to a new ear of drugs to treat Alzheimer’s disease – the world's most common form of dementia.
A survey looking at ayahuasca dangers finds 70% experience physical and 55% mental health adverse effects – but only 2.3% of physical adverse events require medical attention.
